Lumos Pharma - LUMO Total Company Value-to-Revenue Ratio

Lumos Pharma Inc (LUMO) - corporate logo

Lumos Pharma, Inc. (LUMO) maintains a stable management team focused on obtaining regulatory approval for its key drug, a focus supported by the Enterprise Value-to-Revenue multiple. The value characterizes this specific valuation metric. Growth is driven by the development of oral growth hormone secretagogues for rare pathologies. The company's strategy is based on replacing painful injections with convenient tablets, which significantly improves patient adherence to therapy.

LUMO Lumos Pharma, Inc.: Enterprise Value-to-Revenue Ratio in the range 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Lumos Pharma Inc (LUMO)

- cash and cash flow indicators:
Initial company analysis:Lumos Pharma, Inc.
Flagship merchandise of Lumos Pharma

Professional selection of resilient assets requires comparing Enterprise Value (EV) with sales volume to determine the premium paid per unit of revenue regardless of debt load. By analyzing EV/Sales dynamics, an investor assesses the capitalization efficiency of Lumos Pharma, Inc. (LUMO) during the merger of R&D platforms, where cost optimization during the rollout of new drugs directly impacts the company's fundamental attractiveness.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Enterprise Value-to-Revenue Ratio vtvtherapeutics.com (VTVT)|ATPC (Agape ATP) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Pluristem Therapeutics PLUR|SYBX: Company Value to Revenue Ratio|lipocine.com - EV/Sales Multiple|Enterprise Value to Sales Volume MTNB|SPRB: EV/Sales Multiple|Enterprise Value-to-Sales Ratio Galecto Inc GLTO|Enterprise Value-to-Revenue Ratio Carmell Corp|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)